Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (CACTUX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02270814
Recruitment Status : Recruiting
First Posted : October 21, 2014
Last Update Posted : October 1, 2018
Celgene Corporation
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
The purpose of this research study is to look at the effect of a treatment regimen called CACTUX on head and neck cancer. The CACTUX regimen is a combination of three drugs called cisplatin, nab-paclitaxel, and cetuximab (although carboplatin may be given in place of cisplatin if participants have previously had problems receiving cisplatin). The use of nab-paclitaxel in this combination is different from routine care, in which a drug called 5FU is often given instead, but the investigators group has conducted previous research where the investigators incorporated nab-paclitaxel into routine treatment with cisplatin, 5FU, and cetuximab. The investigators are looking at the incidence of side effects with the CACTUX regimen as well as response of the disease and health status.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Cancer of the Head and Neck Drug: nab-paclitaxel Drug: Cisplatin Drug: Carboplatin Biological: Cetuximab Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Actual Study Start Date : February 2, 2015
Estimated Primary Completion Date : May 31, 2019
Estimated Study Completion Date : May 31, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: CACTUX: nab-paclitaxel, cisplatin (or carboplatin), cetuximab

Up to 6 cycles of CACTUX may be given. The CACTUX regimen consists of:

  • nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle followed by
  • cisplatin given intravenously over 60 minutes on an outpatient basis OR carboplatin AUC5 given intravenously over 30 minutes on an outpatient basis on Day 1 of each 21-day cycle followed by
  • cetuximab given intravenously on an outpatient basis of Days 1, 8, and 15 of each 21-day cycle
  • Cisplatin is preferred but carboplatin may be given if the patient has a prior intolerance to cisplatin or at the discretion of the treating physician.

After the completion of 6 cycles of CACTUX, maintenance therapy will be given and consists of:

  • nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1 and 8 of each 21-day cycle
  • cetuximab given intravenously on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle
Drug: nab-paclitaxel
Other Names:
  • Abraxane
  • Albumin-bound paclitaxel
  • Paclitaxel protein-bound

Drug: Cisplatin
Other Names:
  • Cisplatinum
  • CDDP
  • cis-DDP
  • cis-Diamminedichloroplatinum
  • cis-Platinum II
  • DDP

Drug: Carboplatin
Other Names:
  • Paraplatin®

Biological: Cetuximab
Other Name: Erbitux®

Primary Outcome Measures :
  1. Progression-free survival (PFS) - with first line therapy [ Time Frame: 8 months (estimated median length of treatment) ]
    PFS is defined as the time from randomization to first radiologic confirmation of disease progression, or death from any cause.

Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: Until death (estimated 24 months) ]
    OS is defined as the time from randomization to death.

  2. Overall response rate [ Time Frame: 8 months (estimated median length of treatment) ]

    Overall response rate = complete response + partial response

    Evaluated using RECIST 1.1.

  3. Grade 3 and 4 adverse events [ Time Frame: 9 months (28 days from last dose of study drug with estimated median length of treatment of 8 months) ]

    Adverse events will be recorded from the date of first dose of study drug (nab-paclitaxel) until 28 days after the last dose of study drug.

    The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for all toxicity reporting.

  4. Quality of life [ Time Frame: Baseline, End of cycle 2, End of cycle 6, and End of treatment (estimated median length of treatment is 8 months) ]

    Using the EORTC QLQ-C30, MDADI, FACT-H&N, and FACT/GOG-NTX-4.

    • The EORTC-QLQ-C30 has a total score, one general QOL and one "within the last week" subscale, as well as a single "overall general health" item and a single "overall QOL" item. Scale is from 1-4 with 1 = not at all and 4 = very much on 28 questions. The scale is from 1-7 on 2 questions with 1 = very poor and 7 = excellent.
    • The MDADI has 1 global dysphagia item, physical, function and emotional subscales and one summary scale, which is the sum of the 3 subscales rescaled to 0-100.
    • The FACT instruments have four subscales (physical, social, emotional and functional), as well as 11-12 head and neck cancer-specific questions. The scale goes from 1-4 with 1 = not at all and 4 = very much.

  5. Progression-free survival (PFS) - with maintenance therapy [ Time Frame: 8 months (estimated median length of treatment) ]
    PFS on maintenance therapy is defined as time from first dose of maintenance therapy to first radiologic confirmation of disease progression, or death from any cause.

  6. Disease control [ Time Frame: 8 months (estimated median length of treatment) ]

    Disease control = complete response + partial response + stable disease

    Evaluated using RECIST 1.1

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed incurable HNSCC of the oral cavity, oropharynx, larynx, hypopharynx, and/or Level 1-3 neck node with non-skin SCC and unknown primary. "Incurable" is defined as metastatic disease or a local or regional recurrence in a previously irradiated site that is unresectable (or patient declines resection).
  • Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan, as ≥ 20 mm by chest x-ray, or ≥ 10 mm with calipers by clinical exam per RECIST 1.1.
  • At least 18 years of age.
  • ECOG performance status ≤ 1
  • Adequate hematologic, renal, and hepatic function as defined below:

    • Leukocytes ≥ 3,000/mcL
    • Absolute neutrophil count ≥ 1,500/mcl
    • Platelets ≥ 100,000/mcl
    • Total bilirubin ≤ 1.5 mg/dL
    • AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN, alkaline phosphatase ≤ 2.5 x IULN, unless bone metastasis is present in the absence of liver metastasis
    • Creatinine at or below IULN (males 0.7-1.30 mg/dl; females 0.6-1.10 mg/dl) OR Creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
  • At least 4 months since completion of curative therapy, if given previously.
  • Availability of diagnostic tumor tissue specimens for correlative studies.
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for 3 months after completing treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
  • Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

  • Prior systemic therapy for incurable disease.
  • Grade 2 or higher peripheral neuropathy at screening.
  • A history of other malignancy ≤ 2 years previous; exceptions are malignancies with a negligible risk of metastasis or death (e.g., expected 5-year OS > 90%) that were treated with an expected curative outcome, such as squamous cell carcinoma of the skin, in-situ carcinoma of the cervix uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, incidental finding of prostate cancer (TNM stage of T1a or T1b), or synchronous H&N primaries
  • Currently receiving any other investigational agents.
  • Known brain metastases. Patients with known brain metastases must be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, nab-paclitaxel, or other agents used in the study. Previous grade 1 or 2 allergic reaction to cetuximab is permissible.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant and/or breastfeeding. Patient must have a negative pregnancy test within 72 hours of start of study treatment.
  • Known HIV-positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with the study drugs. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02270814

Contact: Douglas R Adkins, M.D. 314-362-5654

United States, Arkansas
University of Arkansas for Medical Sciences Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Omar Atiq, M.D.    870-535-2800   
Principal Investigator: Omar Atiq, M.D.         
Sub-Investigator: Laura Hutchins, M.D.         
Sub-Investigator: Konstantinos Arnaoutakis, M.D.         
Sub-Investigator: Issam Makhoul, M.D.         
Sub-Investigator: Rangaswamy Govindarajan, M.D.         
Sub-Investigator: Fade Mahmoud, M.D.         
Sub-Investigator: Peter Emanuel, M.D.         
Sub-Investigator: Natasa Milojkovic, M.D.         
Sub-Investigator: Pooja Motwani, M.D.         
Sub-Investigator: Liudmila Schafer, M.D.         
United States, Mississippi
University of Mississippi Medical Center Recruiting
Jackson, Mississippi, United States, 39216
Contact: Robert Hamilton, M.D.    601-984-5590      
Principal Investigator: Robert Hamilton, M.D.         
Sub-Investigator: James T Thigpen, M.D.         
Sub-Investigator: Barbara Craft, M.D.         
Sub-Investigator: Louis Puneky, M.D.         
Sub-Investigator: Jennifer Eubanks, M.D.         
Sub-Investigator: Natale Sheehan, M.D.         
Sub-Investigator: John C Henegan, M.D.         
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Douglas R Adkins, M.D.    314-362-5654   
Principal Investigator: Douglas Adkins, M.D.         
Sub-Investigator: Tanya Wildes, M.D.         
Sub-Investigator: Peter Oppelt, M.D.         
United States, North Dakota
Sanford Roger Maris Cancer Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Mark Gitau, M.D.    701-234-6161      
Principal Investigator: Mark Gitau, M.D.         
Sub-Investigator: Anu Gaba, M.D.         
Sub-Investigator: Louis Geeraerts, M.D.         
Sub-Investigator: Mahendra Gupta, M.D.         
Sub-Investigator: Gerald Gross, M.D.         
Sub-Investigator: Susan Hofland, NP         
Sub-Investigator: Amit Panwalkar, M.D.         
Sub-Investigator: Carrie Pfaff, NP         
Sub-Investigator: John Roll, CNS         
Sub-Investigator: Howard Russell, M.D.         
Sub-Investigator: Denise Snow, M.D.         
Sub-Investigator: Preston Steen, M.D.         
Sub-Investigator: Shelby Terstriep, M.D.         
Sub-Investigator: Matthew Tinguely, M.D.         
Sub-Investigator: Radhakrishna Vegunta, M.D.         
Sub-Investigator: Lorelei Wolf, NP         
United States, South Dakota
Sanford Cancer Center Oncology Clinic and Pharmacy Recruiting
Sioux Falls, South Dakota, United States, 57104
Contact: Steven Powell, M.D.    605-328-8000      
Principal Investigator: Steven Powell, M.D.         
Sub-Investigator: Jonathan Bleecker, M.D.         
Sub-Investigator: Keely Hack, M.D.         
Sub-Investigator: Michael Keppen, M.D.         
Sub-Investigator: James Kuzman, M.D.         
Sub-Investigator: Miroslaw Mazurczak, M.D.         
Sub-Investigator: Amy Sanford, M.D.         
Sub-Investigator: Christopher Sumey, M.D.         
Sub-Investigator: Heather Casper-McLay, CNP         
Sub-Investigator: Avigayil East, CNP         
Sub-Investigator: Matthew Graham, CNP         
Sub-Investigator: Susan Halbritter, CNP         
Sub-Investigator: Kimberly Hamer, CNP         
Sub-Investigator: Shauna Jacobs, CNP         
Sub-Investigator: Jacqueline Kelley, CNP         
Sponsors and Collaborators
Washington University School of Medicine
Celgene Corporation
Principal Investigator: Douglas R Adkins, M.D. Washington University School of Medicine

Additional Information:
Responsible Party: Washington University School of Medicine Identifier: NCT02270814     History of Changes
Other Study ID Numbers: 201410073
First Posted: October 21, 2014    Key Record Dates
Last Update Posted: October 1, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Neoplasms by Site
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action